Effect of a Liquid Toothpaste on Periodontal Disease
Launched by DONG-A PHARMACEUTICAL · Apr 12, 2017
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
The trial was a randomized, double-blind, placebo-controlled, parallel group, single-center(Department of periodontology, Yonsei University Dental Hospital) study.
98 patients were assessed for eligibility. Since two patients did not meet the inclusion criteria, 96 subjects were randomly assigned to either the test group.The test group was provided a liquid toothpaste and a control group received placebo. At the end of the study, results were analyzed for 87 patients : 42 in the test group and 45 in the control group .
The study protocol requested 4 visits- once every two weeks-of each su...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Good general health.
- • Minimum of 20 uncrowned permanent natural teeth (excluding third molars).
- • Initial gingivitis index of 1.1\~2.0 as determined by the use of the Loe and Silness Gingival Index.
- • Signed Informed Consent Form.
- Exclusion Criteria:
- • initial plaque index \<1.5, gingival index \<1.0
- • smoker
- • Chronic disease (uncontrolled diabetes, liver disease, heart disease, kidney disease..)
- • subject who had hemorrhagic medical history or who take antiplatelet agent or anticoagulant
- • subject who need antibiotics for preventive administration
- • subjects who had preventive treatment or treatment for periodontitis in the last three months
- • Use of orthodontic appliances.
- • Pregnant women or women who are breast feeding.
- • Previous participation in any other clinical trial in the last 30 days
- • Judged unsuitable by investigators for other reasons.
About Dong A Pharmaceutical
Dong-A Pharmaceutical is a leading South Korean pharmaceutical company dedicated to the research, development, manufacturing, and marketing of innovative healthcare solutions. Established in 1932, the company has built a strong reputation for its commitment to quality and therapeutic advancements, focusing on areas such as oncology, cardiovascular health, and central nervous system disorders. With a robust pipeline of clinical trials and a global presence, Dong-A Pharmaceutical strives to enhance patient outcomes and improve quality of life through its diverse portfolio of prescription medications and over-the-counter products. The company’s dedication to scientific excellence and collaboration with healthcare professionals positions it as a key player in the pharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Chang-Sung Kim, Ph.D
Study Director
Department of Periodontology, Research Institute for Periodontal Regeneration, College of Dentistry, Yonsei University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials